{"id":6508,"date":"2019-11-21T12:43:16","date_gmt":"2019-11-21T07:13:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6508"},"modified":"2023-06-14T11:47:57","modified_gmt":"2023-06-14T06:17:57","slug":"recent-pharma-happenings-for-gho-truvian-lilly","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gho-truvian-lilly","title":{"rendered":"GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\" id=\"h-global-healthcare-opportunities-gho-capital-a-london-based-healthcare-investment-firm-has-recently-netted-usd-1-1-billion-to-advance-european-healthcare\"><strong>Global Healthcare Opportunities (GHO) Capital, a London-based\nhealthcare investment firm, has recently netted USD 1.1 Billion to advance\nEuropean healthcare. <\/strong><\/h2>\n\n\n\n<p>The company plans to use the proceeds to invest in healthcare companies. Closure of the second round capped at USD 1.1 Billion (Euro 975 Million) is the largest ever private equity fund to be invested in European Healthcare. <\/p>\n\n\n\n<p>The Fund will help in advancing the untouched healthcare\nsectors and untapped pharma market opportunities to facilitate valuable healthcare\naccess to people pan-Europe. <\/p>\n\n\n\n<p>The funding round comprised the participation of investors and\nstakeholders across Europe. <\/p>\n\n\n\n<p>Founded in 2014, GHO has been investing in eight healthcare and pharma companies. However, out of eight, GHO has recently announced disinvestments in two companies namely Caprion Biosciences and Quotient Sciences after successfully delivering growth opportunities. <\/p>\n\n\n\n<p>Using the new fund, the company has already been investing\nin Pharma companies such as Sterling Pharma Solutions, and BioAgilytix, a\nbioanalytical player. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-truvian-sciences-a-us-based-healthcare-company-has-announced-the-closure-of-usd-27-1-million-series-b-financing\"><strong>Truvian Sciences, a US-based healthcare company, has\nannounced the closure of USD 27.1 Million Series B financing. <\/strong><\/h2>\n\n\n\n<p>The company plans to use the funds to further advance the development\nof its benchtop blood tester. The funding round was led by GreatPoint Ventures,\nDNS Capital, Tao Capital Partners along with the existing stakeholder Domain\nAssociates. <\/p>\n\n\n\n<p>The recent funding round brings the total funds to USD 46.3\nMillion till now. <\/p>\n\n\n\n<p>Benchtop Blood tester is aimed to provide lab accurate results within 20 minutes from a small blood sample. The company is planning to expand its tester\u2019s ability by expanding its abilities to check chemistry tests, immunoassays and haematology assays. So far, no single device exists that can perform all the standard assessment at one place. <\/p>\n\n\n\n<p>Truvian\u2019s blood tester aims to offer convenient and accurate results for around 40 diagnostics tests covering the most common tests such as lipid and metabolic panels and complete <a href=\"https:\/\/www.delveinsight.com\/report-store\/blood-coagulation-factor-activators-pipeline-insight\">blood <\/a>cell counts as well as tests for thyroid, liver and kidney. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-eli-lilly-and-company-has-announced-its-proposal-to-invest-usd-400-million-to-expand-its-existing-manufacturing-unit-lilly-technology-center-campus-in-indianapolis\"><strong>Eli Lilly and Company has announced its proposal to invest USD 400 Million to expand its existing manufacturing unit Lilly Technology Center campus in Indianapolis.<\/strong><\/h2>\n\n\n\n<p>The investment will be used to add further value to its\nfacility by enhancing the diabetes portfolio. Moreover, the expansion will also\ncreate approximately 100 new high skilled job opportunities. <\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-foot-market\">Diabetes <\/a>is rising globally. The Diabetes prevalence is on a steady increase. According to a report by the WHO, the number of people living with diabetes has risen from 108 Million in 1980 to 422 Million in 2014. Higher blood sugar level results in associated comorbidities like CVDs thus increasing the chances of deaths. The number of deaths in the year 2012 due to diabetes were reported to be around 2.2 million.<\/p>\n\n\n\n<p>Early diagnosis of the disease can substantially help in controlling diabetes by incorporating certain lifestyle changes such as exercising and by following a strict diet plan. <\/p>\n\n\n\n<p>Moreover, easy access to Insulin at affordable rates will help in the treatment and prevent pre-mature deaths.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Global Healthcare Opportunities (GHO) Capital, a London-based healthcare investment firm, has recently netted USD 1.1 Billion to advance European healthcare. The company plans to use the proceeds to invest in healthcare companies. Closure of the second round capped at USD 1.1 Billion (Euro 975 Million) is the largest ever private equity fund to be invested [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6509,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17824,17826,17822,17821,17823,17825],"industry":[17225],"therapeutic_areas":[17240,17230,17233],"class_list":["post-6508","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-bioagilytix","tag-eli-lilly-and-company","tag-gho-capital","tag-global-healthcare-opportunities","tag-sterling-pharma-solutions","tag-truvian-sciences","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-genito-urinary-system-and-sex-hormones","therapeutic_areas-hematological-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>GHO advances healthcare; Truvian nets USD 27M; Lilly plans expansion<\/title>\n<meta name=\"description\" content=\"Truvian Sciences, a US-based healthcare company, has announced the closure of USD 27.1 Million Series B financing to advance its benchtop blood tester.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gho-truvian-lilly\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GHO advances healthcare; Truvian nets USD 27M; Lilly plans expansion\" \/>\n<meta property=\"og:description\" content=\"Truvian Sciences, a US-based healthcare company, has announced the closure of USD 27.1 Million Series B financing to advance its benchtop blood tester.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gho-truvian-lilly\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-21T07:13:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T06:17:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15170345\/Pharma-news-19-Nov-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GHO advances healthcare; Truvian nets USD 27M; Lilly plans expansion","description":"Truvian Sciences, a US-based healthcare company, has announced the closure of USD 27.1 Million Series B financing to advance its benchtop blood tester.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gho-truvian-lilly","og_locale":"en_US","og_type":"article","og_title":"GHO advances healthcare; Truvian nets USD 27M; Lilly plans expansion","og_description":"Truvian Sciences, a US-based healthcare company, has announced the closure of USD 27.1 Million Series B financing to advance its benchtop blood tester.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gho-truvian-lilly","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-11-21T07:13:16+00:00","article_modified_time":"2023-06-14T06:17:57+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15170345\/Pharma-news-19-Nov-1.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gho-truvian-lilly","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gho-truvian-lilly","name":"GHO advances healthcare; Truvian nets USD 27M; Lilly plans expansion","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gho-truvian-lilly#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gho-truvian-lilly#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15170345\/Pharma-news-19-Nov-1.png","datePublished":"2019-11-21T07:13:16+00:00","dateModified":"2023-06-14T06:17:57+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Truvian Sciences, a US-based healthcare company, has announced the closure of USD 27.1 Million Series B financing to advance its benchtop blood tester.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gho-truvian-lilly"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gho-truvian-lilly#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15170345\/Pharma-news-19-Nov-1.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15170345\/Pharma-news-19-Nov-1.png","width":772,"height":482,"caption":"Pharma news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/15170345\/Pharma-news-19-Nov-1.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BioAgilytix<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eli Lilly and Company<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GHO Capital<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Global Healthcare Opportunities<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sterling Pharma Solutions<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Truvian Sciences<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">BioAgilytix<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly and Company<\/span>","<span class=\"advgb-post-tax-term\">GHO Capital<\/span>","<span class=\"advgb-post-tax-term\">Global Healthcare Opportunities<\/span>","<span class=\"advgb-post-tax-term\">Sterling Pharma Solutions<\/span>","<span class=\"advgb-post-tax-term\">Truvian Sciences<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Nov 21, 2019","modified":"Updated on Jun 14, 2023"},"absolute_dates_time":{"created":"Posted on Nov 21, 2019 12:43 pm","modified":"Updated on Jun 14, 2023 11:47 am"},"featured_img_caption":"Pharma news ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6508"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6508\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6509"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6508"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6508"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}